HONG KONG—Duality Biotherapeutics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is planning an initial public offering (IPO) on the Hong Kong Stock Exchange. While the unit price and further details remain under wraps, the company’s ambitions are clear, with a robust pipeline of 12 innovative ADCs since its establishment in 2019.
Duality Biotherapeutics’ pipeline includes six clinical-stage ADCs, two next-generation bispecific ADCs, and an autoimmune disease ADC, all projected to enter clinical trials from 2024 to 2026. Among these, five have already secured Investigational New Drug (IND) approvals in both the US and China, demonstrating the company’s commitment to advancing targeted cancer therapies.
As of the final feasible date, the company has initiated seven global multi-regional clinical trials across over 230 clinical trial centers in 17 countries, with more than 1000 patients enrolled. This extensive clinical footprint underscores Duality Biotherapeutics’ focus on bringing innovative treatments to a broad patient base.
The company’s innovative ADC assets have caught the attention of leading global biopharmaceutical companies, resulting in strategic partnerships with the likes of BioNTech, BeiGene, and Adcendo. These collaborations are valued at over USD 4 billion, reflecting the market’s confidence in Duality Biotherapeutics’ potential to shape the future of cancer treatment.
The planned IPO is expected to bolster Duality Biotherapeutics’ financial position, supporting the continued development of its ADC pipeline and the expansion of its global clinical trial network. This move aligns with the company’s mission to deliver cutting-edge therapies to patients in need and solidifies its stance as a key player in the rapidly evolving ADC space. – Flcube.com
